🟢 Milestone Pharmaceuticals is trading 7% up in pre-market with no clear catalyst identified

Milestone Pharmaceuticals is trading 7.01% up at $0.76 in pre-market on October 9, 2026, with no clear company-specific catalyst identified.

• Shares closed at $0.71 on October 8.
• The investor-relations page lists September 24 as its latest press release, announcing enrollment of the first Canadian participant in its Phase 3 ReVeRA-301 trial. That update does not establish a direct reason for the gain.
• Broader market signals are mixed, and the cause remains unclear.